| 2025-12-15 |
详情>>
股本变动：
变动后总股本5358.73万股
变动原因 ▼▲
- 原因：
- The underwriters exercised the option in full and the company issued 1,956,521 shares of common share
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.96美元,归母净利润-4013.2万美元,同比去年增长-26.09%
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-0.65美元,归母净利润-2687.4万美元,同比去年增长-30.41%
|
| 2025-06-26 |
详情>>
内部人交易：
Shefferman Jesse共交易4笔
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.29美元,归母净利润-1191.4万美元,同比去年增长-7.38%
|
| 2025-04-25 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, Luke Beshar, Roger Garceau, M.D. and Gregory Sargen, each to hold office until our Annual Meeting of Stockholders in 2028;
2.To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To approve an amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan;
5.To conduct any other business properly brought before the Annual Meeting.
|
| 2025-03-05 |
详情>>
业绩披露：
2024年年报每股收益-2.17美元,归母净利润-4459.6万美元,同比去年增长-10.33%
|
| 2024-12-05 |
复牌提示：
2024-12-05 09:44:27 停牌，复牌日期 2024-12-05 09:54:27
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.74美元,归母净利润-3182.7万美元,同比去年增长-5.39%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-1.26美元,归母净利润-2060.8万美元,同比去年增长-1.32%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.97美元,归母净利润-1109.5万美元,同比去年增长-22.66%
|
| 2024-04-26 |
股东大会：
将于2024-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, Jane Huang, M.D, Richard Levy, M.D., and Michael Solomon, Ph.D., each to hold office until our Annual Meeting of Stockholders in 2027;
2.To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To approve the Protara Therapeutics, Inc. 2024 Equity Incentive Plan;
5.To approve the Protara Therapeutics, Inc. 2024 Employee Stock Purchase Plan;
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2024-03-13 |
详情>>
业绩披露：
2023年年报每股收益-3.57美元,归母净利润-4042万美元,同比去年增长38.71%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.67美元,归母净利润-3019.9万美元,同比去年增长-11.91%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-1.8美元,归母净利润-2033.9万美元,同比去年增长-5.42%
|
| 2023-04-26 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, Jesse Shefferman, Barry Flannelly, Pharm.D., and Cynthia Smith, each to hold office until our Annual Meeting of Stockholders in 2026;
2.To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-04-27 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, Luke Beshar, Roger Garceau, M.D. and Gregory Sargen, each to hold office until our Annual Meeting of Stockholders in 2025;
2.To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-09召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, Richard Levy, M.D. and Michael Solomon, Ph.D., each to hold office until our Annual Meeting of Stockholders in 2024;
2.To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2020-04-23 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, Jesse Shefferman and Scott Braunstein, M.D., each to hold office until our Annual Meeting of Stockholders in 2023;
2.To ratify the selection by the audit committee of our board of directors of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement;
4.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers;
5.To conduct any other business properly brought before the Annual Meeting.
|
| 2020-01-10 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2018-04-26 |
股东大会：
将于2018-06-08召开股东大会
会议内容 ▼▲
- 1.To elect Timothy P. Noyes, Garen Bohlin and John G. Freund, M.D., as Class I members of the Board of Directors (each a “Class I director”), each to serve for a three-year term until the Company’s 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for Proteon for the fiscal year ending December 31, 2018.
|
| 2017-07-13 |
股东大会：
将于2017-07-31召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal, which we refer to as the “NASDAQ Proposal,” to approve, for purposes of the NASDAQ Listing Rule 5635(d), the issuance of an aggregate of 22,000 shares (the “Preferred Shares”) of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock” and such sale of the Series A Preferred Stock, the “Transaction”), for a purchase price of $1,000 per share, or an aggregate purchase price of $22.0 million, pursuant to a securities purchase agreement by and between the Company and a syndicate of current and new institutional investors (each individually, an “Investor” and, collectively, the “Investors”), led by a fund affiliated with Deerfield Management Company, L.P. (“Deerfield”), and the conversion of the Preferred Shares into shares of our common stock, par value $0.001 per share (the “Common Stock”; the shares of Common Stock issuable upon conversion of the Preferred Shares being referred to as the “Conversion Shares”), in accordance with the terms of our Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation”), which would result in the issuance of securities convertible into more than 20% of our Common Stock outstanding prior to the issuance of the Preferred Shares or the Conversion Shares at a price that may be less than the greater of book or market value of our Common Stock, which requires stockholder approval under applicable NASDAQ Listing Rules.
2.To consider and vote upon a proposal, which we refer to as the “Equity Incentive Plan Proposal,” to approve an amendment to the Company’s 2014 Equity Incentive Plan, as amended, for purposes of taking into account the number of Conversion Shares issuable upon conversion of the Preferred Shares outstanding for purposes of implementing the “evergreen” features of the Company’s 2014 Equity Incentive Plan.
|
| 2017-04-27 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1.To elect Scott A. Canute and Tim Haines, as Class III members of the Board of Directors (each a “Class III director”), each to serve for a three-year term until the Company’s 2020 Annual Meeting of Stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for Proteon for the fiscal year ending December 31, 2017.
|
| 2016-04-20 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1.To elect Hubert Birner, Ph.D. and Stuart A. Kingsley, as Class II directors, each for a three-year term;
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for Proteon for the fiscal year ending December 31, 2016.
|